CDTX News and Press, Cidara Therapeutics Inc. From 09/01/21

Cidara Therapeutics (NASDAQ:CDTX) appoints Preetam Shah, Ph.D., MBA, as CFO and chief business officer, and Shane Ward as chief legal officer and corporate secretary. Prior to joining Cidara, Dr. Shah served as the executive VP, CFO and treasurer for Brainstorm Cell T...

Biotechnology is advancing rapidly, driven by robust investments in new developments and a demand for synthetic biology. The industry is expected to continue to generate significant growth over an extended period. Therefore, Wall Street analysts expect Tarsus (TARS) and Cidara (CDTX) to deliv...

Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies ha...

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the seco...

Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire WASHINGTON , Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of c...

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., Pr...

ERYTECH Pharma S.A. (NASDAQ:ERYP) +99%. Ardelyx (NASDAQ:ARDX) +14% on Q2 earnings Taoping  (NASDAQ:TAOP) +12% signs strategic cooperation agreement with Shenzhen IntelStrat Technology Co., Ltd Atlassian Corporation Plc (NASDAQ:TEAM) +12%. LM Funding America (NASDAQ:LMFA) +...

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical...

Cidara is in clinical trials with a fungus therapy and has an antiviral platform. Its stock price is at rock bottom. Rezafungin latest data update is encouraging, with an FDA submission likely in 2022. For further details see: Cidara Therapeutics: Rezafungin Data Could B...

Cidara Therapeutics (CDTX) posts new analyses from multiple studies of rezafungin, the company's treatment for candidemia at the 31st European Congress of Clinical Microbiology and Infectious Diseases ((ECCMID)).Rezafungin is Cidara’s novel, once-weekly echinocandin...